ArticleAIDS and behavior2022
Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in AIDS and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06411223 (Project Tara), which is not on this map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06411223 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation
Project Tara: Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.AIDS and behavior · 2025Trial
- Patient Perspectives on Leveraging Long-Acting Injectable Antiretroviral Therapy Visits to Improve Chronic Disease Care.AIDS and behavior · 2026Article
- Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study.Infectious diseases and therapy · 2026Article
- Exploring the Interest and Intention to Use Long-Acting Injectable PrEP (LAI-PrEP) Among Gay, Bisexual and Other Men Who Have Sex with Men (GBMSM) in the Netherlands.AIDS and behavior · 2026Article
- Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention.Viruses · 2026Review
- Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open forum infectious diseases · 2025Article
- Who could benefit the most from long-acting antiretroviral therapy? perspectives of HIV care providers and people with HIV in Florida.AIDS care · 2025Article
- Long-Acting Injectable Prep for People Who Inject Drugs at a Syringe Services Program: A Qualitative Acceptability and Feasibility Study.AIDS and behavior · 2025Article
- Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Identifying Access Barriers to PrEP Among Cisgender Black/African American Women in the United States: A Systematic Review of the Literature.Healthcare (Basel, Switzerland) · 2025Review
- Blending De-implementation and Implementation to Promote Adoption of Universal PrEP Guidelines: Determinants, Strategies, and Outcomes.Critical public health · 2025Article
- Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.AIDS research and human retroviruses · 2024Article
- Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system.Implementation science communications · 2024Article
- PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs.Addiction science & clinical practice · 2024Article
- Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV.Open forum infectious diseases · 2024Article
- Centring the health of women across the HIV research continuum.The lancet. HIV · 2024Review
- Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.AIDS patient care and STDs · 2024Article
- Mobility paradoxes: disruptors, benefits, and agency among mobile female sex workers living with HIV in the Dominican Republic and Tanzania.BMC global and public health · 2024Article
- "What Is the Benefit?": Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV.AIDS education and prevention : official publication of the International Society for AIDS Education · 2023Article
- Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States.Open forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 1 country.
Morgan M PhilbinDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY, USA. mp3243@columbia.edu.ORCID http://orcid.org/0000-0001-7608-7921
Sadie BergenDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY, USA.
Carrigan ParishDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY, USA.
Deanna KerriganDepartment of Prevention and Community Health, George Washington University, Washington, DC, USA.
Elizabeth N KinnardDivision of Epidemiology and Biostatistics, UC Berkeley School of Public Health, Berkeley, CA, USA.
Sarah ReedDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY, USA.
Mardge H CohenDepartment of Medicine, John H. Stroger Jr Hospital of Cook County, Chicago, IL, USA.
Oluwakemi SosanyaDepartment of Medicine, Montefiore, Bronx, NY, USA.
Anandi N ShethDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Adaora A AdimoraDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Jennifer CocohobaDepartment of Clinical Pharmacy, University of California at San Francisco School of Pharmacy, San Francisco, CA, USA.
Lakshmi GoparajuDepartment of Medicine, Georgetown University Medical Center, Washington, DC, USA.
Elizabeth T GolubDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Michael VaughnHIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, Columbia University, New York, NY, USA.
José I GutierrezPhilip R. Lee Institute for Health Policy Studies, University of California, San Francisco, USA.
Margaret A FischlDepartment of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Maria AlcaideDepartment of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Lisa R MetschDepartment of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, NY, USA.
Columbia University · USUniversity of Miami · USBerkeley Public Health Division · USEmory University · USGeorgetown University · USGeorge Washington University · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USMontefiore Medical Center · USNew York Psychoanalytic Society and Institute · USNew York University · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US
Funding
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MSF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3MSex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8MSex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2MMACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2MSurviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studiesU01HL146205 · NHLBI · GEORGETOWN UNIVERSITY · PI SEBLE G KASSAYE, DANIEL J MERENSTEIN · 2019 to 2026
$23.5MMWCCS: The Chicago Cook County Clinical Research SiteU01HL146245 · NHLBI · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI Audrey French, Ryan Dee Ross · 2019 to 2026
$23.3MUNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2MMiami MACS-WIHS Combined Cohort Study Clinical Research SiteU01HL146203 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE, Deborah Lynne Jones · 2019 to 2026
$21.2MFoundation for the National Institutes of Health MACS/WIHS HL146203NCATS NIH HHS UL1 TR000004NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIDA NIH HHS K01 DA039804NIDA NIH HHS K01DA039804ANIMH NIH HHS R34 MH124552NIMH NIH HHS T32 MH019139
Abstract
Long-acting injectable (LAI) modalities have been developed for ART and PrEP. Women face unique barriers to LAI use yet little research has examined women's perceptions of potential LAI HIV therapy candidates. We conducted 89 in-depth interviews at six Women's Interagency HIV Study (WIHS) sites with women living with HIV (n = 59) and HIV-negative women (n = 30) from 2017 to 2018. Interviews were recorded, transcribed, and analyzed using thematic content analysis. Participants identified specific sub-populations who could most benefit from LAI over daily pills: (1) young people; (2) women with childcare responsibilities; (3) people with adherence-related psychological distress; (4) individuals with multiple sex partners; and (5) people facing structural insecurities such as homelessness. Women are underserved by current HIV care options and their perspectives are imperative to ensure a successful scale-up of LAI PrEP and LAI ART that prioritizes equitable access and benefit for all individuals.
Indexed as
Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentCitiesFemaleHumansPatient Acceptance of Health CareUnited StatesAnti-HIV AgentsAntiretroviral therapy (ART)HIV/AIDSLong-acting injectable (LAI)Pre-exposure prophylaxis (PrEP)Qualitative researchWomen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06411223ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.